{"title": "Jap\u00f3n invertir\u00e1 en el pa\u00eds: \u00bfy en Farma?", "author": "Equipo de Redacci\u00f3n", "url": "https://www.pharmabiz.net/japon-invertira-en-el-pais-y-en-farma/", "hostname": "pharmabiz.net", "description": "El primer ministro japon\u00e9s, Shinzo Abe, llegar\u00e1 el pr\u00f3ximo mes a la Argentina. Ser\u00e1 para lubricar inversiones cercanas a los u$s 9.000 millones. El antecedente de esta visita se remonta a mayo pasado, cuando la vicepresidenta de la naci\u00f3n Gabriela Michetti desembarc\u00f3 en ese pa\u00eds en una visita protocolar. Desde Jap\u00f3n ya se dijo que est\u00e1n mirando con...", "sitename": "PharmaBiz.NET", "date": "2016-10-31", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Jap\u00f3n puso la lupa en la Argentina. Planea invertir un monto cercano a los u$s 9.000 millones en las industrias de energ\u00eda; miner\u00eda; infraestructura y agronegocios.\nEl primer ministro japon\u00e9s, Shinzo Abe, llegar\u00e1 el pr\u00f3ximo mes a la Argentina. Ser\u00e1 para lubricar inversiones cercanas a los u$s 9.000 millones.\nEl antecedente de esta visita se remonta a mayo pasado, cuando la vicepresidenta de la naci\u00f3n Gabriela Michetti desembarc\u00f3 en ese pa\u00eds en una visita protocolar. Desde Jap\u00f3n ya se dijo que est\u00e1n mirando con gran atenci\u00f3n a las industrias de energ\u00eda, miner\u00eda, infraestructura y agronegocios.\nEs por eso que no se espera que haya ning\u00fan mega anuncio de las farmac\u00e9uticas niponas durante dicho encuentro. De hecho, el mercado local muestra una escasa presencia de los laboratorios de ese pa\u00eds. Tal es el caso de Takeda, que opera en la Argentina y recientemente anunci\u00f3 el desarrollo de una vacuna contra el zika con el financiamiento del gobierno de los Estados Unidos.\n[Ver art\u00edculo](https://www.pharmabiz.net/takeda-otra-por-la-carrera-del-zika/)\nOtra compa\u00f1\u00eda japonesa que est\u00e1 despleg\u00e1ndose en el continente latino es Astellas. En la Argentina la empresa no tiene filial propia. Sin embargo, sus marcas est\u00e1n licenciadas en manos de las firmas nacionales Raffo y Gador. El antif\u00fangico Mycamine y el producto indicado para el tratamiento de pacientes con c\u00e1ncer de pr\u00f3stata Xtandi est\u00e1n bajo el paraguas de Raffo; mientras que el inmunosupresor Prograf y Omnic, indicado para la hiperplasia benigna de pr\u00f3stata; que son comercializados por Gador.\n[Ver art\u00edculo](https://www.pharmabiz.net/astellas-viene-por-latam/)\nEntre otras farmac\u00e9uticas que hacen punta en Jap\u00f3n resaltan, por caso, Daiichi-Sankyo; Otsuka; Meiji; y Eisai.", "language": null, "image": "https://www.pharmabiz.net/wp-content/uploads/2016/10/JaponArg.jpg", "pagetype": "article", "links": ["https://www.facebook.com/pharmabizweb/?ref=hl", "https://www.instagram.com/pharmabiz/", "https://www.linkedin.com/company/3122224/admin/", "https://twitter.com/pharmabizweb", "#", "https://www.pharmabiz.net/categoria/ejecutivos/", "https://www.pharmabiz.net/categoria/empresas/", "https://www.pharmabiz.net/categoria/informes/", "https://www.pharmabiz.net/categoria/latinoamerica/", "https://www.pharmabiz.net/categoria/regulaciones/", "https://www.pharmabiz.net/categoria/licitaciones-publicas/", "#", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/categoria/canal-hospitalario/", "https://www.pharmabiz.net/categoria/otc/", "https://www.pharmabiz.net/categoria/coyuntura/", "https://www.pharmabiz.net/categoria/resultados-financieros/", "https://www.pharmabiz.net/categoria/resumen-semanal/", "https://www.pharmabiz.net/categoria/retail/", "https://www.pharmabiz.net/categoria/salud-animal/", "https://www.pharmabiz.net/suscripcion/", "https://www.pharmabiz.net/categoria/english-versions/", "#", "#", "#", "#", "#", "https://www.pharmabiz.net/about/", "https://www.pharmabiz.net/evolucion/", "https://www.pharmabiz.net/staff/", "https://www.pharmabiz.net/micros-radiales/", "https://www.pharmabiz.net/pharmabiz-en-los-medios/", "https://www.pharmabiz.net/categoria/versao-em-portugues/", "#", "#", "http://www.ares-enderiz.com/", "https://www.audifarmsalud.com/", "#", "https://www.pharmabiz.net/", "https://www.pharmabiz.net/", "https://www.pharmabiz.net/categoria/ejecutivos/", "https://www.pharmabiz.net/categoria/empresas/", "https://www.pharmabiz.net/categoria/informes/", "https://www.pharmabiz.net/categoria/latinoamerica/", "https://www.pharmabiz.net/categoria/regulaciones/", "https://www.pharmabiz.net/categoria/licitaciones-publicas/", "#", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/categoria/canal-hospitalario/", "https://www.pharmabiz.net/categoria/otc/", "https://www.pharmabiz.net/categoria/coyuntura/", "https://www.pharmabiz.net/categoria/resultados-financieros/", "https://www.pharmabiz.net/categoria/resumen-semanal/", "https://www.pharmabiz.net/categoria/retail/", "https://www.pharmabiz.net/categoria/salud-animal/", "https://www.pharmabiz.net/suscripcion/", "https://www.pharmabiz.net/categoria/english-versions/", "https://www.facebook.com/pharmabizweb/?ref=hl", "https://www.instagram.com/pharmabiz/", "https://www.linkedin.com/company/3122224/admin/", "https://twitter.com/pharmabizweb", "#", "#", "https://www.pharmabiz.net/", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/categoria/empresas/", "https://www.pharmabiz.net/categoria/featured-slider/", "https://www.pharmabiz.net/author/team-pharmabiz/", "#", "https://www.pharmabiz.net/takeda-otra-por-la-carrera-del-zika/", "https://www.pharmabiz.net/astellas-viene-por-latam/", "https://www.facebook.com/sharer.php?u=https%3A%2F%2Fwww.pharmabiz.net%2Fjapon-invertira-en-el-pais-y-en-farma%2F", "https://twitter.com/intent/tweet?text=Jap%C3%B3n+invertir%C3%A1+en+el+pa%C3%ADs%3A+%C2%BFy+en+Farma%3F&url=https%3A%2F%2Fwww.pharmabiz.net%2Fjapon-invertira-en-el-pais-y-en-farma%2F&via=PharmaBiz.NET", "https://pinterest.com/pin/create/button/?url=https://www.pharmabiz.net/japon-invertira-en-el-pais-y-en-farma/&media=https://www.pharmabiz.net/wp-content/uploads/2016/10/JaponArg.jpg&description=Jap%C3%B3n+invertir%C3%A1+en+el+pa%C3%ADs%3A+%C2%BFy+en+Farma%3F", "whatsapp://send?text=Jap%C3%B3n+invertir%C3%A1+en+el+pa%C3%ADs%3A+%C2%BFy+en+Farma%3F %0A%0A https://www.pharmabiz.net/japon-invertira-en-el-pais-y-en-farma/", "https://www.linkedin.com/shareArticle?mini=true&url=https://www.pharmabiz.net/japon-invertira-en-el-pais-y-en-farma/&title=Jap%C3%B3n+invertir%C3%A1+en+el+pa%C3%ADs%3A+%C2%BFy+en+Farma%3F", "mailto:?subject=Jap\u00f3n invertir\u00e1 en el pa\u00eds: \u00bfy en Farma?&body=https://www.pharmabiz.net/japon-invertira-en-el-pais-y-en-farma/", "#", "https://www.pharmabiz.net/hipoglos-con-muestra-gratis/", "https://www.pharmabiz.net/red-parf-en-conferencia/", "https://www.pharmabiz.net/author/team-pharmabiz/", "https://www.pharmabiz.net/author/team-pharmabiz/", "#", "#", "https://www.pharmabiz.net/scienza-recibio-el-sello-verde/", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/scienza-recibio-el-sello-verde/", "https://www.pharmabiz.net/sanidad-asueto-en-instituciones/", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/sanidad-asueto-en-instituciones/", "https://www.pharmabiz.net/coyuntura-resumen-de-noticias-168/", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/coyuntura-resumen-de-noticias-168/", "https://www.pharmabiz.net/pami-las-farmacias-pierden-a-los-panales/", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/pami-las-farmacias-pierden-a-los-panales/", "https://www.pharmabiz.net/acino-adquiere-m8-latam/", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/acino-adquiere-m8-latam/", "https://www.pharmabiz.net/mabxience-y-abbott-cierran-partnership/", "https://www.pharmabiz.net/categoria/agenda/", "https://www.pharmabiz.net/mabxience-y-abbott-cierran-partnership/", "#", "#", "https://www.pharmabiz.net/biogen-arrancaron-los-recortes-y-mas/", "https://www.pharmabiz.net/categoria/informes/", "https://www.pharmabiz.net/biogen-arrancaron-los-recortes-y-mas/", "https://www.pharmabiz.net/author/cris-kroll/", "https://www.pharmabiz.net/sandoz-sale-de-argentina-tras-acuerdo-con-biosidus/", "https://www.pharmabiz.net/categoria/informes/", "https://www.pharmabiz.net/sandoz-sale-de-argentina-tras-acuerdo-con-biosidus/", "https://www.pharmabiz.net/author/cristinalaura/", "https://www.pharmabiz.net/servier-desvincula-apms-y-tambalea-filial-local/", "https://www.pharmabiz.net/categoria/empresas/", "https://www.pharmabiz.net/servier-desvincula-apms-y-tambalea-filial-local/", "https://www.pharmabiz.net/author/cris-kroll/", "https://www.pharmabiz.net/pharmabiz-llega-a-los-15-anos-en-este-2022/", "https://www.pharmabiz.net/categoria/15-aniversario-%f0%9f%8e%88/", "https://www.pharmabiz.net/pharmabiz-llega-a-los-15-anos-en-este-2022/", "https://www.pharmabiz.net/author/cris-kroll/", "https://www.pharmabiz.net/osde-sigue-el-desgrane-de-profesionales/", "https://www.pharmabiz.net/categoria/informes/", "https://www.pharmabiz.net/osde-sigue-el-desgrane-de-profesionales/", "https://www.pharmabiz.net/author/florencia-lippo/", "https://www.pharmabiz.net/sobreseimiento-penal-para-pharmabiz/", "https://www.pharmabiz.net/categoria/informes/", "https://www.pharmabiz.net/sobreseimiento-penal-para-pharmabiz/", "https://www.pharmabiz.net/author/team-pharmabiz/", "https://www.pharmabiz.net/", "mailto:info@pharmabiz.net", "https://www.facebook.com/pharmabizweb/?ref=hl", "https://www.instagram.com/pharmabiz/", "https://www.linkedin.com/company/3122224/admin/", "https://twitter.com/pharmabizweb"]}